Crystalline β-lactam intermediate
    2.
    发明授权
    Crystalline β-lactam intermediate 有权
    结晶β-内酰胺中间体

    公开(公告)号:US06949641B2

    公开(公告)日:2005-09-27

    申请号:US10001544

    申请日:2001-10-31

    CPC分类号: C07D501/00

    摘要: The novel intermediate compound crystalline 7-[2-(2-fomylaminothiazol-4-yl)-2 -(Z)-(methoxyimino)acetamido]-3-methoxymethyl-3-cephem-4-carboxylic acid-1 -(isopropoxy/crystallization of cefpodoxime proxetil. The crystallization process comprises dissolving or suspending the intermediate in the presence of a nitrile or a ketone or mixtures thereof; at a ratio of 1 gm of the intermediate to 2-15 ml nitrile; or at a ratio of 1 gm of the intermediate to 3-15 ml ketone; in the presence of 5-80 ml water; and thereafter isolating the intermediate in crystalline form and converting the intermediate by splitting off the formyl group from the amino group attached to the thiazolyl group, to obtain the desired product cefpodoxime proxetil, in the form of a diastereoisomeric mixture in a ratio of B/(A+B) of 0.5 to 0.6.

    摘要翻译: 新型中间体化合物结晶7- [2-(2-夫酰氨基噻唑-4-基)-2-(Z) - (甲氧基亚氨基)乙酰氨基] -3-甲氧基甲基-3-头孢烯-4-羧酸-1-(异丙氧基/ 结晶方法包括在腈或酮或其混合物的存在下将中间体溶解或悬浮;以1gm中间体与2-15ml腈的比例或以1g的比例 的中间体至3-15ml酮;在5-80ml水的存在下,然后分离出结晶形式的中间体,并通过从连接到噻唑基的氨基分离甲酰基转化中间体,得到 以B /(A + B)比为0.5至0.6的非对映异构体混合物形式的所需产品头孢泊肟酯。

    Derivatives of 3-pyrrolidylidene-2-one-cephalsporines
    5.
    发明授权
    Derivatives of 3-pyrrolidylidene-2-one-cephalsporines 失效
    3-吡咯烷亚基-2-单头孢菌素的衍生物

    公开(公告)号:US5925632A

    公开(公告)日:1999-07-20

    申请号:US875563

    申请日:1997-07-25

    CPC分类号: C07D501/00 Y02P20/55

    摘要: Compounds of formula (I) ##STR1## wherein R.sup.1 is hydrogen, lower alkyl, aralkyl, cycloalkyl, R.sup.3 CO-- or --C(R.sup.4 R.sup.5)CO.sub.2 R.sup.6 ; where R.sup.4 and R.sup.5 are each independently hydrogen or lower alkyl, or R.sup.4 and R.sup.5 taken together with the carbon atom to which they are attached form a cycloalkyl group; R.sup.3 is hydrogen or lower alkyl and R.sup.6 is hydrogen, lower alkyl, lower alkenyl or a carboxylic acid protecting group;R.sup.2 is isobutyl, 2,2-dimethyl-propyl or cyclohexyl-methyl;n is 0, 1 or 2;X is CH or N;as well as readily hydrolyzable esters thereof, pharmaceutically acceptable salts of said compounds and hydrates of the compounds of formula I and of their esters and salts are disclosed. These compounds have valuable antibacterial activity.

    摘要翻译: PCT No.PCT / EP96 / 00667 Sec。 371日期1997年7月25日 102(e)日期1997年7月25日PCT提交1996年2月16日PCT公布。 公开号WO96 / 26943 日期:1996年9月6日,式(I)化合物,其中R1为氢,低级烷基,芳烷基,环烷基,R3CO-或-C(R4R5)CO2R6; 其中R 4和R 5各自独立地为氢或低级烷基,或者R 4和R 5与它们所连接的碳原子一起形成环烷基; R3是氢或低级烷基,R6是氢,低级烷基,低级烯基或羧酸保护基; R2是异丁基,2,2-二甲基 - 丙基或环己基 - 甲基; n为0,1或2; X是CH或N; 以及其易水解的酯,所述化合物的药学上可接受的盐和式I化合物及其酯和盐的水合物被公开。 这些化合物具有有价值的抗菌活性。

    Process for the preparation of cephalosporanic compounds
    10.
    发明授权
    Process for the preparation of cephalosporanic compounds 失效
    制备头孢菌素化合物的方法

    公开(公告)号:US5574154A

    公开(公告)日:1996-11-12

    申请号:US315329

    申请日:1994-09-29

    申请人: Omar Abu-Nasrieh

    发明人: Omar Abu-Nasrieh

    IPC分类号: C07D501/00 C07D501/06

    CPC分类号: C07D501/00

    摘要: The invention relates to a process for the preparation of a compound of the formula I or salts thereof ##STR1## wherein R.sub.1 is hydrogen or trityl,R.sub.2 is hydrogen, trityl, .dbd.NOCH.sub.3, .dbd.NOCH.sub.2 COOH, or .dbd.NOCCOOH(CH.sub.3).sub.2R.sub.3 is hydrogen, --CH.dbd.CH.sub.2, --CH.sub.2 COCH.sub.3, ##STR2## comprising (a) reacting a compound of the formula II ##STR3## wherein R.sub.1 and R.sub.2 are as defined above with a compound of the formula III ##STR4## wherein R.sub.3 is as defined above in the presence of a solvent; (b) refluxing the mixture in the presence of a base; and, (c) if required the compounds of the formula I so obtained are converted into salts thereof. The compounds of the formula I have antibacterial activity.

    摘要翻译: 本发明涉及制备式I化合物或其盐的方法,其中R1是氢或三苯甲基,R2是氢,三苯甲基,= NOCH3,= NOCH2COOH或= NOCCOOH(CH3)2 R3是 氢,-CH = CH 2,-CH 2 COCH 3,其中R 1和R 2如上定义,其中(a)使式II化合物II与式 式III其中R 3如上所定义,在溶剂存在下; (b)在碱的存在下回流混合物; 和(c)如果需要,所得到的式I化合物被转化为其盐。 式I的化合物具有抗菌活性。